

**VINEAL CREAM  
CLOBETASOLE PROPIONATE CREAM USP**

**INDIA**

**1.3.1 Summary of Product Characteristics (SmPC)**

**1. Name of Medicinal Product**

**VINEAL CREAM**

**CLOBETASOLE PROPIONATE CREAM USP**

**2. Qualitative and Quantitative Composition**

**2.1. Qualitative declaration:**

**Composition of the Drug product:**

Clobetasol Propionate USP 0.05% w/w

Colour: FD & C RED NO 3 IHS

Fragrance: 130016 IHS

Cream Base Q.S.

**Qualitative & Quantitative Composition Formula:**

**Batch Size: 1000 Kg**

Sr. No.	Name of Ingredient	Specification	Label Claim	O.A % per Caps	Std. Qty (kg)	Function
<b>Active Ingredients</b>						
1.	Clobetasol Propionate	USP	0.05% w/w	---	0.500	<b>Active</b>
<b>Excipients</b>						
2.	Macrogol cetosteryl ether (Cetomacrogol 1000 BP) 3.00% w/w	BP		--	30.00	<b>Pharmaceutical Aid (Vehicle)</b>
3.	Cetosteryl Alcohol 8.00% w/w	BP		--	80.00	<b>Anti-oxidant</b>
4.	Methyl paraben 0.15% w/w	BP		--	1.500	<b>Preservative</b>
5.	Propyl paraben 0.005% w/w	BP		--	0.500	<b>Preservative</b>
6.	White soft paraffin White Petroleum Jelly) 10.00% w/w	BP		--	100.00	<b>Base</b>
7.	Chlorocresol 0.038% w/w	BP			0.380	<b>Preservative</b>

**GOPALDAS VISRAM & CO. LTD.**

A-590/591, TTC Ind. Area, MIDC Industrial Area, Mahape, Navi Mumbai, Maharashtra-400710. India.

**VINEAL CREAM  
CLOBETASOLE PROPIONATE CREAM USP**

**INDIA**

8.	Propylene Glycol 5.00 % w/w	BP			50.00	<b>Preservative</b>
9.	Sodium dihydrogen phosphate Dihydrate (Sodium acid phosphate) 0.025% w/w	BP			0.250	<b>Pharmaceutical Aid (Vehicle)</b>
10.	Fragrance 130016 0.18% w/w	IHS			1.800	<b>Flavour</b>
11.	Colour: FD & C RED NO 3 0.0001952% w/w	IHS			0.0019	<b>Colour</b>
12.	Purified water	BP			Q.S to 1000 kg	<b>Solvent</b>

**3. Pharmaceutical Form**

Cream

White semisolid cream.

**4. Clinical Particulars**

**4.1. Therapeutic indications:**

Clobetasol is a very potent topical corticosteroid indicated for adults, elderly and children over 1 year for the short term treatment only of more resistant inflammatory and pruritic manifestations of steroid responsive dermatoses unresponsive to less potent corticosteroids. These include the following:

- Psoriasis (excluding widespread plaque psoriasis)
- Recalcitrant dermatoses
- Lichen planus
- Discoid lupus erythematosus
- Other skin conditions which do not respond satisfactorily to less potent steroids.

**4.2 Posology and method of administration**

Route of administration: Cutaneous

Creams are especially appropriate for moist or weeping surfaces.

---

**GOPALDAS VISRAM & CO. LTD.**

A-590/591, TTC Ind. Area, MIDC Industrial Area, Mahape, Navi Mumbai, Maharashtra-400710. India.

**Adults, Elderly and Children over 1 year**

Apply thinly and gently rub in using only enough to cover the entire affected area once or twice a day until improvement occurs (in the more responsive conditions this may be within a few days), then reduce the frequency of application or change the treatment to a less potent preparation. Allow adequate time for absorption after each application before applying an emollient.

Repeated short courses of clobetasol propionate may be used to control exacerbations.

In more resistant lesions, especially where there is hyperkeratosis, the effect of clobetasol can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory response. Thereafter improvement can usually be maintained by application without occlusion.

If the condition worsens or does not improve within 2-4 weeks, treatment and diagnosis should be re-evaluated.

Treatment should not be continued for more than 4 weeks. If continuous treatment is necessary, a less potent preparation should be used.

The maximum weekly dose should not exceed 50gms/week.

Therapy with clobetasol should be gradually discontinued once control is achieved and an emollient continued as maintenance therapy.

Rebound of pre-existing dermatoses can occur with abrupt discontinuation of clobetasol.

**Recalcitrant dermatoses: Patients who frequently relapse**

Once an acute episode has been treated effectively with a continuous course of topical corticosteroid, intermittent dosing (once daily, twice weekly, without occlusion) may be considered. This has been shown to be helpful in reducing the frequency of relapse.

Application should be continued to all previously affected sites or to known sites of potential relapse. This regimen should be combined with routine daily use of emollients. The condition and the benefits and risks of continued treatment must be re-evaluated on a regular basis.

**Paediatric population**

VINEAL CREAM is contraindicated in children under one year of age.

Children are more likely to develop local and systemic side effects of topical corticosteroids and, in general, require shorter courses and less potent agents than adults.

Care should be taken when using clobetasol propionate to ensure the amount applied is the minimum that provides therapeutic benefit.

**Duration of treatment for children and infants**

Courses should be limited if possible to five days and reviewed weekly. Occlusion should not be used.

**Application to the face**

Courses should be limited to five days if possible and occlusion should not be used.

**Elderly**

Clinical studies have not identified differences in responses between the elderly and younger patients. The greater frequency of decreased hepatic or renal function in the elderly may delay elimination if systemic absorption occurs. Therefore the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.

**Renal / Hepatic Impairment**

In case of systemic absorption (when application is over a large surface area for a prolonged period) metabolism and elimination may be delayed therefore increasing the risk of systemic toxicity. Therefore the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.

**4.3 Contraindications**

Hypersensitivity to the active substance or any of the excipients listed in section 6.1.

The following conditions should not be treated with VINEAL CREAM:

- Untreated cutaneous infections
- Rosacea
- Acne vulgaris
- Pruritus without inflammation
- Perianal and genital pruritus
- Perioral dermatitis.

Clobetasol is contraindicated in dermatoses in children under one year of age, including dermatitis and nappy eruptions.

#### **4.4 Special warnings and precautions for use**

Clobetasol should be used with caution in patients with a history of local hypersensitivity to other corticosteroids or to any of the excipients in the preparation. Local hypersensitivity reactions (*see section 4.8*) may resemble symptoms of the condition under treatment.

Manifestations of hypercortisolism (Cushing's syndrome) and reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, leading to glucocorticosteroid insufficiency, can occur in some individuals as a result of increased systemic absorption of topical steroids. If either of the above are observed, withdraw the drug gradually by reducing the frequency of application, or by substituting a less potent corticosteroid. Abrupt withdrawal of treatment may result in glucocorticosteroid insufficiency (*see section 4.8*).

VINEAL CREAM contains:

- propylene glycol which may cause skin irritation.
- cetostearyl alcohol which may cause local skin reactions (e.g. contact dermatitis).
- chlorocresol which may cause allergic reactions.

Risk factors for increased systemic effects are:

- Potency and formulation of topical steroid
- Duration of exposure
- Application to a large surface area
- Use on occluded areas of skin (e.g. on intertriginous areas or under occlusive dressings (in infants the nappy may act as an occlusive dressing))
- Increasing hydration of the stratum corneum
- Use on thin skin areas such as the face
- Use on broken skin or other conditions where the skin barrier may be impaired
- In comparison with adults, children and infants may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic adverse effects. This is because children have an immature skin barrier and a greater surface area to body weight ratio compared with adults.

#### **Paediatric population**

In infants and children under 12 years of age, long-term continuous topical corticosteroid therapy should be avoided where possible, as adrenal suppression can occur

Children are more susceptible to develop atrophic changes with the use of topical corticosteroids.

**Duration of treatment for children and infants**

Courses should be limited if possible to five days and reviewed weekly. Occlusion should not be used.

**Infection risk with occlusion**

Bacterial infection is encouraged by the warm, moist conditions within skin folds or caused by occlusive dressings. When using occlusive dressings, the skin should be cleansed before a fresh dressing is applied.

**Use in Psoriasis**

Topical corticosteroids should be used with caution in psoriasis as rebound relapses, development of tolerances, risk of generalised pustular psoriasis and development of local or systemic toxicity due to impaired barrier function of the skin have been reported in some cases. If used in psoriasis careful patient supervision is important.

**Concomitant infection**

Appropriate antimicrobial therapy should be used whenever treating inflammatory lesions which have become infected. Any spread of infection requires withdrawal of topical corticosteroid therapy and administration of appropriate antimicrobial therapy.

**Chronic leg ulcers**

Topical corticosteroids are sometimes used to treat the dermatitis around chronic leg ulcers. However, this use may be associated with a higher occurrence of local hypersensitivity reactions and an increased risk of local infection.

**Application to the face**

Application to the face is undesirable as this area is more susceptible to atrophic changes. If used on the face, treatment should be limited to 5 days.

**Application to the eyelids**

If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye, as cataract and glaucoma might result from repeated exposure. If clobetasone does enter the eye, the affected eye should be bathed in copious amounts of water.

**Visual disturbance**

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may

include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

Co-administered drugs that can inhibit CYP3A4 (eg ritonavir and itraconazole) have been shown to inhibit the metabolism of corticosteroids leading to increased systemic exposure. The extent to which this interaction is clinically relevant depends on the dose and route of administration of the corticosteroids and the potency of the CYP3A4 inhibitor.

#### **4.6. Use in pregnancy and lactation:**

##### **Pregnancy**

There are limited data from the use of clobetasol in pregnant women.

Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development (see section 5.3)

The relevance of this finding to humans has not been established. Administration of clobetasol during pregnancy should only be considered if the expected benefit to the mother outweighs the risk to the foetus. The minimum quantity should be used for the minimum duration.

##### **Breast-feeding**

The safe use of topical corticosteroids during lactation has not been established.

It is not known whether the topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable amounts in breast milk. Administration of clobetasol during lactation should only be considered if the expected benefit to the mother outweighs the risk to the infant.

If used during lactation clobetasol should not be applied to the breasts to avoid accidental ingestion by the infant.

##### **Fertility**

There are no data in humans to evaluate the effect of topical corticosteroids on fertility

Clobetasol administered subcutaneously to rats had no effect upon mating performance; however, fertility was decreased at the highest dose (*see section 5.3*).

**4.7 Effects on ability to drive and use machines**

There have been no studies to investigate the effect of clobetasol on driving performance or the ability to operate machinery. A detrimental effect on such activities would not be anticipated from the adverse reaction profile of topical clobetasol.

**4.8 Undesirable effects**

Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency. Frequencies are defined as: very common ( $\geq 1/10$ ), common ( $\geq 1/100$  and  $< 1/10$ ), uncommon ( $\geq 1/1,000$  and  $< 1/100$ ), rare ( $\geq 1/10,000$  and  $< 1/1,000$ ) and very rare ( $< 1/10,000$ ), including isolated reports.

**Post-marketing data**

**Infections and Infestations**

Very rare                                      Opportunistic infection

**Immune System Disorders**

Very rare                                      Hypersensitivity, generalised rash

**Endocrine Disorders**

Very rare                                      Hypothalamic-pituitary adrenal (HPA) axis suppression:  
Cushingoid features: (e.g. moon face, central obesity), delayed weight gain/growth retardation in children, osteoporosis, glaucoma, hyperglycaemia/glucosuria, cataract, hypertension, increased weight/obesity, decreased endogenous cortisol levels, alopecia, trichorrhexis

**Skin and Subcutaneous Tissue Disorders**

Common                                      Pruritus, local skin burning /skin pain

Uncommon                                    Skin atrophy\*, striae\*, telangiectasias\*

Very rare                                      Skin thinning\*, skin wrinkling\*, skin dryness\*, pigmentation changes\*, hypertrichosis, exacerbation of underlying symptoms, allergic contact dermatitis/dermatitis, pustular psoriasis, erythema, rash, urticaria, acne





## **5.2 Pharmacokinetic properties**

### **Absorption**

Topical corticosteroids can be systemically absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.

Mean peak plasma clobetasol propionate concentrations of 0.63 ng/ml occurred in one study eight hours after the second application (13 hours after an initial application) of 30 g clobetasol propionate 0.05% ointment to normal individuals with healthy skin. Following the application of a second dose of 30 g clobetasol propionate cream 0.05% mean peak plasma concentrations were slightly higher than the ointment and occurred 10 hours after application.

In a separate study, mean peak plasma concentrations of approximately 2.3 ng/ml and 4.6 ng/ml occurred respectively in patients with psoriasis and eczema three hours after a single application of 25 g clobetasol propionate 0.05% ointment.

### **Distribution**

The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids is necessary due to the fact that circulating levels are well below the level of detection.

### **Metabolism**

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. They are metabolised, primarily in the liver.

### **Elimination**

Topical corticosteroids are excreted by the kidneys. In addition, some corticosteroids and their metabolites are also excreted in the bile.

## **5.3 Preclinical safety data**

### **Carcinogenesis / Mutagenesis**

#### **Carcinogenesis**

Long-term animal studies have not been performed to evaluate the carcinogenic potential of clobetasol propionate.

**Genotoxicity**

Clobetasol propionate was not mutagenic in a range of *in vitro* bacterial cell assays.

**Reproductive Toxicology**

**Fertility**

In fertility studies, subcutaneous administration of clobetasol propionate to rats at doses of 6.25 to 50 micrograms/kg/day produced no effects on mating, and fertility was only decreased at 50 micrograms/kg/day.

**Pregnancy**

Subcutaneous administration of clobetasol propionate to mice ( $\geq 100$  micrograms/kg/day), rats (400 micrograms/kg/day) or rabbits (1 to 10 micrograms/kg/day) during pregnancy produced foetal abnormalities including cleft palate and intrauterine growth retardation.

In the rat study, where some animals were allowed to litter, developmental delay was observed in the F1 generation at  $\geq 100$  micrograms/kg/day and survival was reduced at 400 micrograms/kg/day. No treatment-related effects were observed in F1 reproductive performance or in the F2 generation.

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of Excipients**

Macrogol cetosteryl ether (Cetomacrogol 1000 BP) 3.00% w/w	BP
Cetosteryl Alcohol 8.00% w/w	BP
Methyl paraben 0.15% w/w	BP
Propyl paraben 0.005% w/w	BP
White soft paraffin White Petroleum Jelly) 10.00% w/w	BP
Chlorocresol 0.038% w/w	BP
Propylene Glycol 5.00 % w/w	BP
Sodium dihydrogen phosphate Dihydrate (Sodium acid phosphate) 0.025% w/w	BP
Fragrance 130016 0.18% w/w	IHS
Colour: FD & C RED NO 3 0.0001952% w/w	IHS
Purified water	BP

**6.2 Incompatibilities**

None Known

**6.3 Shelf life**

36 years

**6.4 Special precautions for storage**

Keep below 30°C. Protect from light.

**6.5 Nature and contents of container**

50 gm of VINEAL CREAM is packed in a lami tube and such one tube packed in a carton with package insert.

**6.6 Special precautions for disposal and other handling**

No special requirements.

**7- Marketing Authorization Holder:**

**VIXA PHARMACEUTICALS LTD.,**

**13B, Sunny Jigide Street, Off. Celestial way, Ogudu, Lagos, Nigeria.**

**8- Marketing Authorization Number (s):**

**Product license / registration Number (s)**

-----

**9- Manufacturer Name:**

**GOPALDAS VISRAM & CO. LTD.**

A-590/591, TTC Ind. Area, MIDC Industrial Area, Mahape, Navi Mumbai, Maharashtra-400710. India.